PMV Pharmaceuticals
PMVP
55 hedge funds and large institutions have $40.7M invested in PMV Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 32 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3.42% less ownership
Funds ownership: 75.28% → 71.87% (-3.4%)
21% less funds holding
Funds holding: 70 → 55 (-15)
31% less capital invested
Capital invested by funds: $58.8M → $40.7M (-$18.2M)
72% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 32
85% less call options, than puts
Call options by funds: $2K | Put options by funds: $13K
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.66M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$381K |
| 3 |
SCM
Sio Capital Management
New York
|
+$222K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$128K |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$59.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$673K |
| 2 |
M&T Bank
Buffalo,
New York
|
-$604K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$557K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$486K |
| 5 |
Two Sigma Advisers
New York
|
-$284K |
PMVP Hedge Fund Activity: Q1 2025 in Review
55 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2025, worth a combined $40.7M — down 31% from $58.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PMVP and 1 opened new positions — a net loss of 15 holders — while 32 trimmed existing stakes and 9 added.
The largest buyer was PFM Health Sciences, adding an estimated $1.66M. The largest seller was Citigroup, cutting an estimated $673K.
- 55 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2025, down from 70 in Q4 2024.
- Funds reported $40.7M of PMV Pharmaceuticals stock for Q1 2025, down 31% quarter-over-quarter.
- 1 fund opened new PMV Pharmaceuticals positions in Q1 2025 and 16 closed out, a net change of -15 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2025 was PFM Health Sciences, an estimated $1.66M added.
- The largest PMV Pharmaceuticals seller in Q1 2025 was Citigroup, an estimated $673K sold.
Based on aggregated 13F filings for Q1 2025.